The bioavailability of L-carnitine from oral supplements (doses, 0.6 to 7 g) ranges between 5% and 25% of the total dose (5)
Archived (PDF) from the original on 28 August 2017
These drugs bind to the GLP-1 receptor and: Lower blood sugar by increasing insulin and reducing glucagon Slow gastric emptying Reduce appetite and food cravings Support clinically significant weight loss in many people They are commonly prescribed for: Type 2 diabetes Obesity or overweight with weight-related health risks Trials suggest GLP-1 agonists can reduce body weight by around 5 to 18 per cent on average, often with improvements in blood pressure, cholesterol and other cardiometabolic markers
Human epidemiological data presents mixed results, though some studies indicate correlations between elevated IGF-1 levels and increased risk of certain cancers, particularly breast, prostate, and colorectal cancers
References Roberts CK, Hevener AL, Barnard RJ: Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training